Agile Therapeutics Inc. (NASDAQ: AGRX) stock jumped 5.86% on Monday to $0.30 against a previous-day closing price of $0.28. With 0.92 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.9 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $0.3040 whereas the lowest price it dropped to was $0.2850. The 52-week range on AGRX shows that it touched its highest point at $15.60 and its lowest point at $0.17 during that stretch. It currently has a 1-year price target of $3.00. Beta for the stock currently stands at 1.04.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AGRX was up-trending over the past week, with a rise of 2.21%, but this was up by 69.37% over a month. Three-month performance surged to 12.06% while six-month performance fell -45.16%. The stock lost -97.79% in the past year, while it has gained 30.57% so far this year. A look at the trailing 12-month EPS for AGRX yields -14.93 with Next year EPS estimates of -0.67. For the next quarter, that number is -0.23. This implies an EPS growth rate of -26.00% for this year and 71.10% for next year.
Float and Shares Shorts:
At present, 37.00 million AGRX shares are outstanding with a float of 36.81 million shares on hand for trading. On Oct 13, 2022, short shares totaled 1.22 million, which was 3.14% higher than short shares on Sep 14, 2022. In addition to Mr. Alfred F. Altomari as the firm’s Chairman & CEO, Mr. Geoffrey P. Gilmore serves as its Sr. VP, Chief Admin. Officer & Corp. Sec.
Through their ownership of 0.55% of AGRX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 4.71% of AGRX, in contrast to 0.93% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in AGRX with 1.31% of the stake, Perceptive Advisors LLC holds 532,361 shares worth 532,361. A second-largest stockholder of AGRX, LPL Financial LLC, holds 411,506 shares, controlling over 1.01% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in AGRX, holding 303,741 shares or 0.75% stake. With a 0.51% stake in AGRX, the Fidelity Extended Market Index Fu is the largest stakeholder. A total of 208,839 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.19% of AGRX stock, is the second-largest Mutual Fund holder. It holds 76,860 shares valued at 17447.0. Diamond holds 0.15% of the stake in AGRX, owning 60,050 shares worth 13631.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AGRX since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AGRX analysts setting a high price target of $3.00 and a low target of $1.00, the average target price over the next 12 months is $2.00. Based on these targets, AGRX could surge 900.0% to reach the target high and rise by 233.33% to reach the target low. Reaching the average price target will result in a growth of 566.67% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. AGRX will report FY 2022 earnings on 02/28/2024. Analysts have provided yearly estimates in a range of -$2.42 being high and -$2.50 being low. For AGRX, this leads to a yearly average estimate of -$2.46. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Agile Therapeutics Inc. surprised analysts by -$0.09 when it reported -$0.53 EPS against a consensus estimate of -$0.44. The surprise factor in the prior quarter was $0.99. Based on analyst estimates, the high estimate for the next quarter is -$0.21 and the low estimate is -$0.23. The average estimate for the next quarter is thus -$0.22.
Summary of Insider Activity:
Insiders traded AGRX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 8 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 54,690 while 0 shares were sold.